Clinical stage medical sensor company Lifecare ASA (Euronext Growth Oslo:LIFE) on Wednesday announced positive results from nine weeks of longevity trial for its Sencell continuous glucose monitor (CGM).
The sensor, implanted in a dog named Elli, has successfully operated for over two months and continues to collect data.
The primary goal of the trial is to assess the sensor's long-term operational lifetime and biocompatibility. Elli, the first patient, is in good health and shows no signs of discomfort from the implant.
Lifecare's CEO, Joacim Holter, emphasised the sensor's impressive longevity compared to existing CGM systems on the market. The company is now preparing to enrol additional patients in the study to further validate the sensor's performance and gather more data on glucose readings in both healthy and diabetic dogs.
Lifecare Veterinary's managing director, Jo Amundstad, said that the company is in discussions with regulatory authorities to extend the implant period to 24 weeks or longer. This will allow for further evaluation of the sensor's long-term impact on tissues.
Adocia patents stable hormone combinations for obesity and diabetes
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
GMSS Holdings acquires DDP Medical Supply
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Xylyx Bio receives SBIR grant from NIDDK
Lilly expands manufacturing footprint in Ireland
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lifecare sensor achieves 9-week longevity in dog trial
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Sumitomo Pharma and Poxel report positive results from TWYMEEG study in Japan